Experimental cancer drug trial halted early
NCT ID NCT06299761
First seen Jan 22, 2026 · Last updated May 09, 2026 · Updated 23 times
Summary
This early-stage trial tested a new oral drug, BBI-825, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could help control the cancer when used alone or with other targeted therapies. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
Irving, Texas, 75039, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarcoma Oncology Research Center
Santa Monica, California, 90403, United States
Conditions
Explore the condition pages connected to this study.